376 related articles for article (PubMed ID: 30116859)
1. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
[TBL] [Abstract][Full Text] [Related]
2. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Rotroff DM; Corum DG; Motsinger-Reif A; Fiehn O; Bottrel N; Drevets WC; Singh J; Salvadore G; Kaddurah-Daouk R
Transl Psychiatry; 2016 Sep; 6(9):e894. PubMed ID: 27648916
[TBL] [Abstract][Full Text] [Related]
4. 7T
Evans JW; Lally N; An L; Li N; Nugent AC; Banerjee D; Snider SL; Shen J; Roiser JP; Zarate CA
Neuropsychopharmacology; 2018 Aug; 43(9):1908-1914. PubMed ID: 29748628
[TBL] [Abstract][Full Text] [Related]
5. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Nugent AC; Wills KE; Gilbert JR; Zarate CA
Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
7. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Nugent AC; Ballard ED; Gould TD; Park LT; Moaddel R; Brutsche NE; Zarate CA
Mol Psychiatry; 2019 Jul; 24(7):1040-1052. PubMed ID: 29487402
[TBL] [Abstract][Full Text] [Related]
8. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
[TBL] [Abstract][Full Text] [Related]
9. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
10. Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
Lundin NB; Sepe-Forrest L; Gilbert JR; Carver FW; Furey ML; Zarate CA; Nugent AC
J Affect Disord; 2021 Jan; 279():239-249. PubMed ID: 33074143
[TBL] [Abstract][Full Text] [Related]
11. The role of adipokines in the rapid antidepressant effects of ketamine.
Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
[TBL] [Abstract][Full Text] [Related]
12. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
Niciu MJ; Iadarola ND; Banerjee D; Luckenbaugh DA; Park M; Lener M; Park L; Ionescu DF; Ballard ED; Brutsche NE; Akula N; McMahon FJ; Machado-Vieira R; Nugent AC; Zarate CA
J Psychopharmacol; 2017 Dec; 31(12):1570-1577. PubMed ID: 29039254
[TBL] [Abstract][Full Text] [Related]
13. Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.
Moaddel R; Zanos P; Farmer CA; Kadriu B; Morris PJ; Lovett J; Acevedo-Diaz EE; Cavanaugh GW; Yuan P; Yavi M; Thomas CJ; Park LT; Ferrucci L; Gould TD; Zarate CA
Transl Psychiatry; 2022 May; 12(1):179. PubMed ID: 35501309
[TBL] [Abstract][Full Text] [Related]
14. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
[TBL] [Abstract][Full Text] [Related]
15. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
16. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA
J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.
Villaseñor A; Ramamoorthy A; Silva dos Santos M; Lorenzo MP; Laje G; Zarate C; Barbas C; Wainer IW
Br J Pharmacol; 2014 Apr; 171(8):2230-42. PubMed ID: 24684390
[TBL] [Abstract][Full Text] [Related]
18. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
19. Role of copper and ketamine in major depressive disorder - an update.
Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
[TBL] [Abstract][Full Text] [Related]
20. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
